Design of gp120 HIV-1 entry inhibitors by scaffold hopping via isosteric replacements

Eur J Med Chem. 2021 Nov 15:224:113681. doi: 10.1016/j.ejmech.2021.113681. Epub 2021 Jul 7.

Abstract

We present the development of alternative scaffolds and validation of their synthetic pathways as a tool for the exploration of new HIV gp120 inhibitors based on the recently discovered inhibitor of this class, NBD-14136. The new synthetic routes were based on isosteric replacements of the amine and acid precursors required for the synthesis of NBD-14136, guided by molecular modeling and chemical feasibility analysis. To ensure that these synthetic tools and new scaffolds had the potential for further exploration, we eventually tested few representative compounds from each newly designed scaffold against the gp120 inhibition assay and cell viability assays.

Keywords: Drug discovery; HIV; Lead optimization; Screening; Synthesis; gp120.

MeSH terms

  • Binding Sites
  • Cell Line
  • Cell Survival / drug effects
  • Drug Design*
  • HIV Envelope Protein gp120 / antagonists & inhibitors*
  • HIV Envelope Protein gp120 / metabolism
  • HIV Fusion Inhibitors / chemistry*
  • HIV Fusion Inhibitors / metabolism
  • HIV Fusion Inhibitors / pharmacology
  • HIV-1 / drug effects
  • HIV-1 / metabolism*
  • Humans
  • Molecular Docking Simulation
  • Structure-Activity Relationship
  • Thiazoles / chemistry
  • Thiazoles / metabolism
  • Thiazoles / pharmacology
  • Virus Internalization / drug effects

Substances

  • HIV Envelope Protein gp120
  • HIV Fusion Inhibitors
  • Thiazoles